Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia
Status:
Active, not recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of eltrombopag in people who
have myelodysplastic syndrome (MDS) with thrombocytopenia who have progressed or are
resistant to decitabine or azacitidine. (These are the only 2 drugs approved by the U.S. Food
and Drug Administration [FDA] which can improve platelet counts). The investigators (the
study doctor, study staff, and sponsor) want to find out what effects, good or bad,
eltrombopag (study drug) may have on people with low platelet counts due to MDS. The
investigators will also be testing how well eltrombopag may work at different doses in these
diseases.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute